Good news!
"The drug KarXT, sold as Cobenfy, gained regulatory approval in the United States in September, making it the first approved schizophrenia drug targeting muscarinic receptors found throughout the brain and body. Hailed by some as a new era of psychiatric medicine, pharma company Bristol Myers Squibb is now trialling the drug to treat psychosis associated with Alzheimer’s disease. KarXT’s active ingredient acts on muscarinic M1 receptors, which are linked to cognition, and M4 receptors, which are most strongly associated with antipsychotic effects."
"Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in September ... About half a dozen similar drugs — for schizophrenia, Alzheimer’s disease and other conditions involving the brain — are in various stages of development, most in early-stage clinical trials. But the success of these medicines is not a given. Last week, a trial of a highly anticipated schizophrenia drug reported disappointing results.
For decades, schizophrenia drugs worked in essentially the same way. They blunted the activity of dopamine, a chemical involved in the disorder’s hallmark symptoms, such as hallucinations and delusions. The new kid on the block is KarXT, sold as Cobenfy. It targets muscarinic receptors and leads to antipsychotic and cognitive benefits. ..."
For decades, schizophrenia drugs worked in essentially the same way. They blunted the activity of dopamine, a chemical involved in the disorder’s hallmark symptoms, such as hallucinations and delusions. The new kid on the block is KarXT, sold as Cobenfy. It targets muscarinic receptors and leads to antipsychotic and cognitive benefits. ..."
New schizophrenia drug could treat Alzheimer’s disease (partial public access) "Half a dozen drugs are in trials for conditions of the brain, but success is not guaranteed."
No comments:
Post a Comment